Revvity (RVTY) Q1 2025 10-Q Quarterly Report

Filed: May 6, 2025Period ending Mar 30, 2025
Health Care
Laboratory Analytical InstrumentsSEC EDGAR

Revvity (RVTY) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 6, 2025 for the fiscal period ending Mar 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Revvity Q1 2025 10-Q Analysis

Management Discussion & Analysis

  • Revenue $664.8M, up 2% YoY from $649.9M; Life Sciences $340.4M (+1%), Diagnostics $324.4M (+3%)
  • Gross margin 56.5% vs 54.6% YoY; SG&A margin 37.6% vs 40.1% YoY; R&D margin 8.1% vs 7.7% YoY
  • Best segment: Life Sciences operating income $105.7M (+5%), margin +106bps; Worst: Diagnostics operating income $74.0M (-3%), margin down 150bps
  • Cash and equivalents $1.14B; Operating cash flow $134.1M vs $150.1M YoY; $153.6M stock repurchases vs $10.8M
  • Management expects 20% effective tax rate for FY25; tariff impact on operating income approx. $20M; share repurchase program $707.2M remaining

Risk Factors

  • New risk: Cautious customer spending due to recent and proposed U.S. funding and regulatory uncertainties impacting government and industrial funding approvals
  • Most materially updated risk: Increased supply chain risks from global conflicts and tariffs, including Ukraine war and retaliatory trade measures affecting costs and delivery
  • Regulatory risk: Heightened data privacy and information security laws, with potential significant fines and operational impacts for noncompliance in U.S., EU, and UK markets
  • Near-term operational risk: Significant disruption risk in third-party shipping providers like UPS and DHL, potentially increasing costs and delaying deliveries, affecting profitability
  • Financial risk: Substantial debt with multi-year notes due 2026 to 2051, variable rate exposure, foreign currency risk, and restrictive covenants limiting financial and operational flexibility

Revvity Q1 2025 Quarterly Financials
XBRL

Revenue

$665M

+2.3% YoY

Net Income

$42M

+62.4% YoY

Net Margin

6.4%

+235bp YoY

Source: XBRL data from Revvity Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Revvity Quarterly Reports

Get deeper insights on Revvity

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.